How Systemic Eczema Therapies Change the Skin Bacteriome: A Pilot Study

Research-focused microbiome review; not a treatment recommendation.

The study question

A prospective pilot evaluated the skin bacteriome of people with atopic dermatitis receiving systemic therapies including cyclosporine, dupilumab and JAK inhibitors, alongside topical treatment context. Researchers asked whether clinical improvement was accompanied by changes in bacterial community structure.

Why paired sampling is useful

Collecting samples before and after treatment lets each participant serve partly as their own control. Linking swabs with EASI, itch or barrier measures can reveal whether microbial shifts track disease improvement. Comparing therapy classes may also generate mechanistic hypotheses.

Why causality remains unresolved

When inflammation improves, scratching, oozing, topical use and Staphylococcus abundance can change. Therefore, a microbial shift may be a consequence of better skin rather than the mechanism producing it. Antibiotics, bathing, body site, season and sampling depth also affect results. A pilot is not powered to establish rare taxa or definitive between-drug differences.

Do not choose treatment by microbiome headline

Systemic therapies are selected according to severity, comorbidities, age, pregnancy considerations, previous treatment and safety profile. No commercial microbiome test currently replaces standard clinical evaluation. Patients should not add antimicrobials or probiotics based on a sequencing result without professional advice.

Infant caution

Adult systemic-treatment findings do not apply to babies. Infant eczema and infection signs require pediatric assessment. Unsupervised antiseptics, antibiotics or live microbes can create harm.

Bottom line

The pilot shows how microbial ecology can be studied alongside modern therapy. It cannot prove that bacteriome remodeling is necessary for—or causes—clinical response.

Related Dr. Arsy research

• Choosing an eczema moisturizer
• Eczema and sleep research guide
• Childhood eczema and school performance
• Comparing eczema treatments
• Targeted-therapy tapering evidence
• Recognizing eczema across skin tones

References

1. Systemic therapies and skin bacteriome pilot
2. Abrocitinib and the skin microbiome study
3. Oral microbiome with dupilumab or upadacitinib
4. Topical Lactobacillus lactis pilot trial
5. Washed microbiota transplantation study
6. Qing-Re-Qu-Shi multi-omics randomized trial
7. Nature-based microbial exposure pilot
8. Child dupilumab skin and gut microbiome pilot
9. Pediatric skin-microbiome emollient trial
10. Pediatric gut and skin microbiota case-control study
11. XZ.700 endolysin randomized trial
12. Staphylococcus hominis A9 safety trial
13. B244 itch randomized trial
14. Farnesol moisturizer microbiome study
15. AAD topical therapy guideline
16. AAD systemic therapy guideline
17. AAAAI/ACAAI GRADE guideline
18. Atopic dermatitis microbiome review
19. Staphylococcus aureus and atopic dermatitis review
20. Skin microbiome in atopic dermatitis review
21. Dupilumab SOLO phase 3 trials
22. Upadacitinib Measure Up trials
23. Abrocitinib JADE MONO-1 trial
24. HOME core outcome set

Referenced researchers do not endorse Dr. Arsy products.